NOV 06, 2019 10:30 AM PST

Drug discovery and pharmacology of antivirals targeting drug-resistant influenza viruses

Presented at: Influenza 2019
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
    Biography
      Dr. Wang received his bachelor degree in chemistry from Wuhan University, China, in 2003. After a one year industry experience in a biotechnology company, he joined Dr. Shaoqin Yao's group at the National University of Singapore in 2004 as a graduate student. His thesis project involves designing and developing chemical probes and inhibitors for matrix metalloproteases. After receiving his master degree in 2006, he moved to the United States and started his PhD study in Dr. William F. DeGrado's laboratory at the University of Pennsylvania. His PhD thesis focuses on rational design of inhibitors targeting drug-resistant influenza A virus M2 proton channels. He is also a major contributor in developing chemical probes to solve the scientific controversy of the drug binding site(s) of M2. After receiving his PhD in chemistry in 2010, he continued as a postdoctoral researcher in the DeGrado lab, first at the University of Pennsylvania and later at the University of California, San Francisco. He started his independent career as an assistant professor at the College of Pharmacy, University of Arizona in 2014. His laboratory mainly focuses on medicinal chemistry and pharmacology of antivirals. Research in the Wang Laboratory is directed towards developing antivirals targeting drug-resistant viruses and emerging viruses, including influenza A and B viruses, enterovirus D68 (EV-D68), EV-A71, coxsackievirus, and polio virus. They are developing inhibitors against multiple viral proteins and use them as chemical probes for target validation. For influenza virus, they have developed inhibitors targeting the M2 proton channel, the viral polymerase PA-PB1 protein-protein interactions, and the hemagglutinin fusion protein. For enteroviruses, they have designed inhibitors targeting the viral capsid VP1 protein, the viral 2A protease, the viral 2C protein, and the viral polymerase. In addition, they are also interested in developing host-targeting antivirals as a means to address drug resistance.

    Abstract

    The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antivirals by targeting the drug-resistant mutants of M2 and the viral polymerase. In this presentation, I will introduce our work in designing inhibitors targeting the viral M2-S31N mutant proton channel and the viral polymerase PA-PB1 interactions. The designed M2-S31N inhibitors and the PA-PB1 inhibitors have been shown to inhibit drug resistant influenza viruses with potent antiviral efficacy and a high selectivity index. 


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 06, 2019 10:30 AM PST

    Drug discovery and pharmacology of antivirals targeting drug-resistant influenza viruses

    Presented at: Influenza 2019
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Molecular Biology

    Clinical Diagnostics

    Immunology

    Microbiology

    Biotechnology

    Infectious Disease

    Cancer Research

    Laboratory Testing

    Biochemistry

    Gene Expression

    Dna

    Animal Research

    Biomarkers

    Genomics

    Cancer Diagnostics

    Geography

    Asia56%

    North America37%

    Europe7%

    Registration Source

    Website Visitors85%

    Email Promotions11%

    Social Media Promotions4%

    Job Title

    Student38%

    Research Scientist13%

    Medical Laboratory Technician13%

    Medical Doctor/Specialist8%

    Educator/Faculty8%

    Microbiologist8%

    Clinical Laboratory Scientist4%

    Veterinarian4%

    Lab Management4%

    Organization

    Academic Institution52%

    Medical School7%

    Research Institute7%

    Clinical Laboratory7%

    General Laboratory4%

    Hospital4%

    Pharmaceutical Company4%

    Medical Center4%

    Veterinary School4%

    Government4%

    Manufacturer - Other4%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more